Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07547540 | A Study of LY3971297 in Participants With Heart Failure | PHASE1 | NOT YET_RECRUITING | 90 | — | — | Jun 1, 2026 | Aug 1, 2027 | May 22, 2026 | 3 | United States, Japan |
| Arm | Type | Description |
|---|---|---|
| LY3971297 Part A Cohort 1 | EXPERIMENTAL | LY3971297 administered subcutaneously (SC) |
| Placebo Part A Cohort 1 | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3971297 Part A Cohort 2 | EXPERIMENTAL | LY3971297 administered SC |
| Placebo Part A Cohort 2 | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3971297 Part A Cohort 3 | EXPERIMENTAL | LY3971297 administered SC |
| Placebo Part A Cohort 3 | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3971297 Part A Cohort 4 | EXPERIMENTAL | LY3971297 administered SC |
| Placebo Part A Cohort 4 | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3971297 Part A Cohort 5 | EXPERIMENTAL | LY3971297 administered intravenously (IV) |
| Placebo Part A Cohort 5 | PLACEBO_COMPARATOR | Placebo administered IV |
| LY3971297 Part B | EXPERIMENTAL | LY3971297 administered SC or IV |
| Placebo Part B | PLACEBO_COMPARATOR | Placebo administered SC or IV |
| Name | Type | Description |
|---|---|---|
| LY3971297 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Are diagnosed with chronic heart failure with New York Heart Association Class II-III (Heart Failure) HF symptomatology at screening and on guideline-directed HF therapy for at least 6 months prior to screening. * Have not changed optimal guideline-directed HF therapy, either ...